Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

6.45USD
4:00pm EDT
Change (% chg)

$-0.24 (-3.59%)
Prev Close
$6.69
Open
$6.66
Day's High
$6.75
Day's Low
$6.43
Volume
148,042
Avg. Vol
342,111
52-wk High
$9.18
52-wk Low
$4.45

Latest Key Developments (Source: Significant Developments)

Ziopharm Q4 loss per share $0.11
Thursday, 16 Feb 2017 04:05pm EST 

Ziopharm Oncology Inc : Ziopharm reports fourth-quarter 2016 financial results and provides update on recent activities . Q4 loss per share $0.11 .Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Ziopharm Q2 loss per share $1.01
Tuesday, 9 Aug 2016 04:01pm EDT 

Ziopharm Reports Second : Q2 loss per share $1.01 . Quarter 2016 financial results and provides update on recent activities . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Ziopharm oncology inc says recognized approximately $1.7 million in revenue during quarter in comparison with $0.3 million in revenue in 2015.  Full Article

Ziopharm Oncology updates on early study for brain cancer drug
Friday, 15 Jul 2016 09:25am EDT 

Ziopharm Oncology Inc : Ziopharm issues statement regarding phase 1 study of gene therapy candidate ad-RTS-hIL-12 in brain cancer . "first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug" . "for patients that remain in follow up in this phase i study, we believe that preliminary overall survival remains encouraging" . Third death has just been reported, collecting and analyzing information in order to properly and timely report it to fda . There have been no reported related instances of brain hemorrhage in pervious cohort or prior studies with ad-RTS-hIL-12 + veledimex . Cause of death for third patient is intracranial hemorrhage, which occurred some time after patient had been discharged from treating center .Enrollment remains open in study, will be discussing with safety review committee appropriate course of action.  Full Article

Intrexon and Ziopharm amend exclusive channel collaborations
Thursday, 30 Jun 2016 08:00am EDT 

Ziopharm Oncology Inc : Intrexon and Ziopharm amend exclusive channel collaborations to improve alignment as programs advance through development . New structure is intended to facilitate increased investment in clinical development by Ziopharm .Announced amendments to their exclusive channel collaborations (ECCS) in fields of oncology and graft-versus-host-disease.  Full Article

Ziopharm Oncology Q1 loss per share $0.09
Tuesday, 10 May 2016 04:05pm EDT 

Ziopharm Reports First : Quarter 2016 financial results and provides update on recent activities . Q1 loss per share $0.09 .Q1 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S.  Full Article

ZIOPHARM Oncology Inc announces data highlighting Ad-RTS-hIL-12 activity in Glioma at SNO
Thursday, 19 Nov 2015 07:00am EST 

ZIOPHARM Oncology Inc:Says announces data highlighting Ad-RTS-hIL-12 activity in Glioma at SNO.Says results show il-12 was detectable in peripheral blood along with downstream IFNG.Says most common adverse events were headache, fever, hyponatremia and nausea/vomiting.  Full Article

Intrexon Corporation and ZIOPHARM to develop immunotherapies for treatment of Graft-Versus-Host Disease
Monday, 28 Sep 2015 04:00pm EDT 

Intrexon Corporation:Says formed a new Exclusive Channel Collaboration (ECC) with ZIOPHARM Oncology.For the treatment and prevention of graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT) which significantly impairs the quality of life and survival of many recipients.Says will receive a technology access fee of $10 million in cash and reimbursement for all research and development costs.Says agreement also provides for equal sharing of operating profits.ECC intends to expand on benefits of IL-2 immunotherapy under co's technologies to generate clinical-grade Tregs that deliver IL-2.  Full Article

ZIOPHARM Oncology Inc announces orphan drug designation for Ad-RTS-hIL-12
Friday, 24 Jul 2015 11:17am EDT 

ZIOPHARM Oncology Inc:Says U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant glioma.AD-RTS-HIL-12 study is expected to enroll up to 72 subjects at up to 12 leading treatment centers.  Full Article

ZIOPHARM Oncology Inc announces initiation of Phase 1 Study of Ad-RTS-IL-12 Gene therapy in patients with brain cancer
Tuesday, 5 May 2015 07:00am EDT 

ZIOPHARM Oncology Inc:Says initiation of Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma or Grade III malignant glioma, form of brain cancer.Says Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, critical protein for stimulating an anti-cancer T cell immune response.Phase 1 study is designed to examine gene therapy treatment strategy for high grade gliomas with the goal of generating an anti tumor T cell immune response.Eligible patients will be stratified to one of two groups, according to clinical indication for tumor resection.One group will undergo resection plus injection and the other group will undergo stereotactic injection.Says Ad-RTS-hIL-12 will be injected locally in the tumor lesion, with IL-12 expression levels tightly regulated by escalating doses of the oral activator ligand veledimex.This strategy makes it feasible to control gene therapy in vivo and to lower or terminate IL-12 expression in the event of severe or unexpected toxicities.Primary objective of study is to determine safety and tolerability of single intra tumoral Ad-RTS-hIL-12 injection plus escalating oral veledimex doses.Secondary objectives to determine veledimex maximum tolerated dose, immune responses elicited by Ad-RTS-hIL-12 and veledimex and investigator assessment of response, including tumor objective response rate and progression-free survival & determine overall survival among other measures.  Full Article

More From Around the Web

BRIEF-Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications

* Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications Source text for Eikon: Further company coverage: